President, Research & Early Development, Celgene Corporation
Vessey is in his current position at Celgene since 2016, and is anticipated to hold that position at Bristol-Myers Squibb once its acquisition of Celgene is final. Previously, he held various research and development senior management positions for ten years at Merck. Before that he worked in drug discovery, experimental medicine, and early clinical development at GlaxoSmithKline.
- 2019 Third Quarter
Added to: Bio-Techne Corporation - Minneapolis, MN
Bio-Techne provides biotechnology reagents, instruments, and clinical diagnostic controls. Revenues are $703 million.